Base egg creature 63.91 million completed the diagnosis of the acquisition of Jingchuan, officially into the blood-clotting track!

Guide: Kiwi Bio acquires 54.96% of Jingchuan Diagnostics, which officially becomes its subsidiary.!----. July 24 Base Egg Biology announced that the Company at a price of 3.42 yuan per share to the transferees to hold a total of about 1868.72 million shares of Wuhan Jingchuan Diagnostics, the transaction amount of 63.91 million yuan.National Share Transfer confirmed that the transaction has completed the transfer of the above-mentioned specific matters agreement on July 21, 2020., Wuhan Jingchuan Diagnostic Technology Co., Ltd. before and after the transfer of shares of the comparison table after the completion of the registration of shares, Keo-Egg Bio officially holds about 186.872 million shares of Jingchuan Diagnostics, accounting for 54.96 percent of Jingchuan Diagnostics total share capital, Jingchuan Diagnostics officially became a controlling subsidiary of the company, and included in the consolidated statements of listed companies.1, Jingchuan diagnostic simple fundamental announcement data show that Jingchuan diagnostics main business for blood coagulation products research and development, production and sales, as well as the sale of other in vitro diagnostic products.Jingchuan Diagnostics since its establishment in 2006, in the research and development of clotting diagnostic reagents, production has accumulated with its own brand and independent intellectual property rights of technology and products.its independent research and development products are BCA series automatic blood clotting instrument, XN06 series, GDC series, BCS series blood clotting instrument, fully automatic C reactive protein analyzer, TD series of specific protein instrument and clotting test kit, specific protein detection kit and more than 50 products.reviewed the financial data, Jingchuan Diagnostics in 2017, 2018 and 2019 achieved revenue of 52.383 million yuan, 58.7407 million yuan, 7011.83 million yuan, and net profit of 4.917 million yuan, 5.171 million yuan, 8.549 million yuan, respectively.2, the base egg to open up the field of clotting detection sub-field base egg biology said that through this acquisition and capital increase, the use of the company in vitro diagnostics in the field of resources, into the industry segment ationd by clotting testing.-based egg biology believes that coagulation testing in cardiovascular disease, cerebrovascular disease diagnosis has important medical significance, so with the company's existing cardiovascular testing business has a strong synergy, help the company to find new profitable growth points.in order to develop the business section of coagulation detection, the base egg biology and Jingchuan diagnostic agreement, the acquirer in a specific sales system under the standard of the company's own production of coagulation reagents (including reagents, cleaning fluids, quality control products) sales indicators and included in the assessment.2020 and 2021 through the acquirer in a specific sales system to complete the target company's self-produced blood clotting reagents revenue target is not less than 2.5 million, 7.5 million.both sides also have agreement on the sales of coagulation reagents: Jingchuan diagnostic 2020 self-produced coagulation reagents sales revenue increased by not less than 30% compared to 2019;, the 2019-2021 target of non-net profit of Jingchuan Diagnostics is 6.5 million yuan, 10 million yuan and 20 million yuan, respectively.3, accelerate the layout of the base egg biological hubei area acquisition Jingchuan diagnosis, will accelerate the layout of the base egg organisms in Hubei region.as early as 2017, the base egg biological in Wuhan set up Hubei-based egg medical equipment Co., Ltd.2018, The Company has invested in the establishment of Yellowstone Medical Medical Inspection Co., Ltd., Hubei Dong Medical Home Pension Services Co., Ltd. from the end of 2018 to the beginning of 2019, Kikome Bio holds Wuhan Dias Technology Co., Ltd., a microbial testing company, through acquisition and capital increase. September 2019, KikoBio took a stake in Wuhan Boko Guotai Information Technology Co., Ltd., a medical big data platform company. is known that of the nearly 30 companies that invest in eggs, more than 20% are located in Hubei, second only to Jiangsu. this time, the base egg biological successfully cut into the clotting test sub-field, Wuhan local IVD enterprise Mingde biological has not yet deeply involved. .